Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

The company said data from a pooled-dose group in the multiple ascending-dose portion of its clinical trial will be compared with a matched natural-history cohort. No efficacy, safety, or financial results were disclosed, limiting the immediate investment implication.